// App-Quantinova.ai

: CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response

Researchers

Presenter

  • Guy Brusselle

Principal Investigators

  • Neil Barnes

  • Roland Buhl

  • Frances Gardiner

  • Liam G. Heaney

  • Hiromasa Inoue

  • Giselle Mosnaim

  • Alberto Papi

  • Emilio Pizzichini

  • Jun Tamaoki

  • Claus F. Vogelmeier

  • Agne Zarankaite

  • Ian Pavord

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Philipps Univ Marburg, Marburg, Germany

  • GSK, Brentford, Middlesex, United Kingdom,

  • NorthShore University HealthSystem, Evanston, IL, United States of America

  • Pulmonary Department, Mainz University Hospital, Mainz, Germany

  • University of Ferrara, Ferrara, Italy

  • Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

  • GSK & Federal University of Santa Catarina, Brentford, Middlesex & Santa Catarina, United Kingdom

  • GSK & William Harvey Institute, Barts and The London School of Medicine and Dentistry, Brentford, Middlesex & London, United Kingdom

  • Hematology, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

  • Centre for Experimental Medicine, Queen’s University Belfast, School of Medicine, Dentistry and Biomed, Belfast, UK

  • OTS, Tokyo, Japan

Locations

  • United States

  • United Kingdom

  • Germany

  • Italy

  • Belgium

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Umeclidinium

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved